Stockscreener 앱 받기
2.47
10.76%
0.24
시간 외 거래:
2.42
-0.05
-2.02%
전일 마감가:
$2.23
열려 있는:
$2.24
하루 거래량:
356.49K
Relative Volume:
1.94
시가총액:
$118.81M
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
+5.11%
1개월 성능:
-19.28%
6개월 성능:
-39.61%
1년 성능:
+0.00%
1일 변동 폭
$2.16
$2.5284
1주일 범위
$2.10
$2.5284
52주 변동 폭
$1.80
$7.20
Tuhura Biosciences Inc Stock (HURA) Company Profile
명칭
Tuhura Biosciences Inc
전화
813-875-6600
주소
10500 UNIVERSITY CENTER DR., TAMPA
HURA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
HURA
Tuhura Biosciences Inc
|
2.47 | 118.81M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.16 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
534.91 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
322.06 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
542.47 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
245.16 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Tuhura Biosciences Inc Stock (HURA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-03-03 | 개시 | H.C. Wainwright | Buy |
| 2024-12-19 | 개시 | Rodman & Renshaw | Buy |
| 2024-11-05 | 개시 | Maxim Group | Buy |
Tuhura Biosciences Inc 주식(HURA)의 최신 뉴스
TuHURA Biosciences (NASDAQ:HURA) Downgraded by Wall Street Zen to “Sell” - Defense World
TuHURA Biosciences Amid Nasdaq Composite Volatility - Kalkine Media
Millennium Management LLC Invests $138,000 in TuHURA Biosciences (NASDAQ:HURA) - Defense World
TuHURA Biosciences Approves Executive Salary Increases - TipRanks
TuHURA Biosciences announces executive salary increases - Investing.com
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates HURA and VIGL on Behalf of Shareholders - PR Newswire
TuHURA Says FDA Lifts Partial Hold on Skin Cancer Study - marketscreener.com
TuHURA Biosciences stock rises following FDA hold lift By Investing.com - Investing.com Nigeria
TuHURA Biosciences stock rises following FDA hold lift - Investing.com
FDA Removes Partial Clinical Hold On TuHURA Biosciences' Phase 3 Accelerated Approval Trial For IFx-2.0 In Advanced Or Metastatic Merkel Cell Carcinoma - marketscreener.com
FDA Removes Partial Clinical Hold on TuHURA Biosciences' Phase 3 Accelerated Approval Trial for IFx-2.0 in Advanced or Metastatic Merkel Cell Carcinoma - PR Newswire
Squarepoint Ops LLC Invests $223,000 in TuHURA Biosciences (NASDAQ:HURA) - Defense World
TuHURA Biosciences Secures $12.6M for Strategic Initiatives - TipRanks
TuHURA Biosciences: Promising Oncology Advancements and Strategic Acquisitions Drive Buy Rating - TipRanks
TuHURA Biosciences raises $15.5 million for cancer trials By Investing.com - Investing.com South Africa
TuHURA Biosciences, Inc. announced that it expects to receive $12.19 million in funding - MarketScreener
TuHURA Biosciences raises $15.5 million for cancer trials - Investing.com
Tuhura Biosciences Secures $12.5 Mln In Private Offering - MarketScreener
TuHURA Biosciences, Inc. Enters into $12.5 Million Equity Financing Transaction and Receives Additional $3.0 Million in Warrant Exercise Proceeds to Advance Its Pipeline of Novel Treatments to Overcome Primary Resistance to Cancer Immunotherapy - The Malaysian Reserve
Northern Trust Corp Makes New Investment in TuHURA Biosciences (NASDAQ:HURA) - Defense World
TuHURA Biosciences Presents IFx-Hu2.0 Trial-in-Progress Poster at the 2025 American Society of Clinical Oncology Annual Meeting - Quantisnow
TuHURA Biosciences: Encountering Serious Cash Issues And A Long Timeline - Seeking Alpha
Kineta and TuHURA Biosciences Announce Merger Agreement - TipRanks
Q3 EPS Estimate for TuHURA Biosciences Decreased by Analyst - Defense World
FY2027 Earnings Estimate for HURA Issued By Zacks Small Cap - Defense World
HURA: First Quarter 2025 Results - MSN
What is HC Wainwright’s Estimate for HURA FY2025 Earnings? - Defense World
HC Wainwright Reaffirms “Buy” Rating for TuHURA Biosciences (NASDAQ:HURA) - Defense World
TuHURA Biosciences, Inc. Reports First Quarter 2025 Financial Results and Provides a Corporate Update - Eagle-Tribune
TuHURA Biosciences Reports First Quarter 2025 Financial Results And Provides A Corporate Update - marketscreener.com
TuHURA Biosciences, Inc. to Present at the 3rd Annual H.C. Wainwright BioConnect Conference - Citizen Tribune
TuHURA Biosciences (HURA) to Release Earnings on Tuesday - Defense World
Kineta Amends Merger Agreement with TuHURA Biosciences - TipRanks
TuHURA Biosciences Amends Merger Agreement with Kineta - TipRanks
TuHURA Biosciences initiates Phase 1b/2a study of IFx-Hu2.0 in carcinoma - TipRanks
TuHURA Biosciences begins trial for metastatic cancer therapy By Investing.com - Investing.com Canada
TuHURA Biosciences begins trial for metastatic cancer therapy - Investing.com
TuHURA Biosciences, Inc. Initiates Phase 1b/2a Study of IFx-Hu2.0 as an Adjunctive Therapy to Keytruda® (pembrolizumab) in First Line Treatment for Metastatic Merkel Cell Carcinoma of Unknown Primary Origin (MCCUP) - PR Newswire
TuHURA Biosciences, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference - ACCESS Newswire
Geode Capital Management LLC Buys New Holdings in TuHURA Biosciences (NASDAQ:HURA) - Defense World
TuHURA Biosciences Reports Cancer Immunotherapy Safe, Well Tolerated in Clinical Trial - marketscreener.com
TuHURA Biosciences and Kineta present updated results of cancer candidates - TipRanks
TuHURA And Kineta Present Updated Results From Phase I-II Study Of KVA12123 - Nasdaq
TuHURA Biosciences and Kineta Present Updated Results from Kineta's Phase I-II Study of KVA12123 and TuHURA's Mechanism of IFx-Hu2.0 Responses After Anti-PD-1 Therapy Failure in Advanced Melanoma at the American Association for Cancer Resea - Eastern Progress
Press Release Distribution & PR Platform - ACCESS Newswire
TuHURA Biosciences, Inc. to Present at the 37th Annual ROTH Conference - ACCESS Newswire
TuHURA Biosciences (NASDAQ:HURA) vs. Lakeshore Biopharma (NASDAQ:LSB) Head-To-Head Contrast - Defense World
Is TuHURA Biosciences, Inc. (HURA) the Best Rising Penny Stock to Buy According to Analysts? - Insider Monkey
Tuhura Biosciences Inc (HURA) 재무 분석
Tuhura Biosciences Inc (HURA)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
0.39%
0.42%
자본화:
|
볼륨(24시간):